$2.59 Billion is the total value of HealthCor Management, L.P.'s 54 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OM | Exit | OUTSET MED INC | $0 | – | -35,000 | -100.0% | -0.07% | – |
| DYN | Exit | DYNE THERAPEUTICS INC | $0 | – | -120,000 | -100.0% | -0.10% | – |
| ATHA | Exit | ATHIRA PHARMA INC | $0 | – | -217,500 | -100.0% | -0.16% | – |
| ALGN | Exit | ALIGN TECHNOLOGY INC | $0 | – | -14,680 | -100.0% | -0.19% | – |
| AMWL | Exit | AMERICAN WELL CORPcl a | $0 | – | -250,000 | -100.0% | -0.30% | – |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INC | $0 | – | -519,490 | -100.0% | -0.34% | – |
| ARCT | Exit | ARCTURUS THERAPEUTICS HLDGScall | $0 | – | -200,000 | -100.0% | -0.34% | – |
| ZYME | Exit | ZYMEWORKS INC | $0 | – | -345,550 | -100.0% | -0.64% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INCcall | $0 | – | -310,000 | -100.0% | -0.93% | – |
| SYK | Exit | STRYKER CORPORATION | $0 | – | -118,550 | -100.0% | -0.99% | – |
| DHR | Exit | DANAHER CORPORATION | $0 | – | -144,600 | -100.0% | -1.25% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -578,030 | -100.0% | -1.73% | – |
| MD | Exit | MEDNAX INC | $0 | – | -3,234,280 | -100.0% | -2.11% | – |
| AMGN | Exit | AMGEN INC | $0 | – | -233,740 | -100.0% | -2.38% | – |
| ARCT | Exit | ARCTURUS THERAPEUTICS HLDGS | $0 | – | -1,594,452 | -100.0% | -2.74% | – |
| REGN | Exit | REGENERON PHARMACEUTICALS | $0 | – | -190,310 | -100.0% | -4.26% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HCA HOLDINGS INC | 27 | Q1 2022 | 6.2% |
| ZIMMER HLDGS INC | 26 | Q2 2022 | 9.3% |
| DANAHER CORPORATION | 26 | Q3 2022 | 5.6% |
| NEUROCRINE BIOSCIENCES INC | 26 | Q4 2022 | 7.8% |
| UNITEDHEALTH GROUP INC | 24 | Q3 2022 | 6.4% |
| VERTEX PHARMACEUTICALS INC | 24 | Q3 2021 | 5.3% |
| HUMANA INC | 22 | Q3 2022 | 6.6% |
| BRISTOL-MYERS SQUIBB CO | 22 | Q3 2022 | 9.2% |
| BIOGEN INC | 21 | Q3 2022 | 8.5% |
| LABORATORY CORP AMER HLDGS | 20 | Q2 2020 | 8.3% |
View HealthCor Management, L.P.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CareView Communications Inc | May 26, 2023 | 186,970,000 | 32.0% |
| Research Alliance Corp. IISold out | February 14, 2023 | 0 | 0.0% |
| ARYA Sciences Acquisition Corp IVSold out | February 14, 2022 | 0 | 0.0% |
| Aurinia Pharmaceuticals Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| MADRIGAL PHARMACEUTICALS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Medicus Sciences Acquisition Corp.Sold out | February 14, 2022 | 0 | 0.0% |
| Arcturus Therapeutics Holdings Inc.Sold out | February 12, 2021 | 0 | 0.0% |
| Intersect ENT, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
| NEVRO CORP | February 12, 2021 | 156,046 | 0.5% |
| ViewRay, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
View HealthCor Management, L.P.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2023-05-26 |
| 4 | 2023-05-26 |
| SC 13D/A | 2023-05-26 |
| 4 | 2023-04-04 |
| 4 | 2023-04-04 |
| SC 13D/A | 2023-04-03 |
| 13F-HR | 2023-02-15 |
| SC 13G/A | 2023-02-14 |
| 4 | 2023-01-04 |
| 4 | 2023-01-04 |
View HealthCor Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.